Cargando…

Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection

Background: Molds and other pathogens induce elevated levels of several cytokines, including interleukin (IL)-6 and IL-8. The objective of this study was to investigate the prognostic value of IL-6 and IL-8 as well as fungal biomarkers in blood and bronchoalveolar lavage fluid (BAL) for overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawlings, Stephen A., Heldt, Sven, Prattes, Juergen, Eigl, Susanne, Jenks, Jeffrey D., Flick, Holger, Rabensteiner, Jasmin, Prüller, Florian, Wölfler, Albert, Neumeister, Peter, Strohmaier, Heimo, Krause, Robert, Hoenigl, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687868/
https://www.ncbi.nlm.nih.gov/pubmed/31428097
http://dx.doi.org/10.3389/fimmu.2019.01798
_version_ 1783442795830181888
author Rawlings, Stephen A.
Heldt, Sven
Prattes, Juergen
Eigl, Susanne
Jenks, Jeffrey D.
Flick, Holger
Rabensteiner, Jasmin
Prüller, Florian
Wölfler, Albert
Neumeister, Peter
Strohmaier, Heimo
Krause, Robert
Hoenigl, Martin
author_facet Rawlings, Stephen A.
Heldt, Sven
Prattes, Juergen
Eigl, Susanne
Jenks, Jeffrey D.
Flick, Holger
Rabensteiner, Jasmin
Prüller, Florian
Wölfler, Albert
Neumeister, Peter
Strohmaier, Heimo
Krause, Robert
Hoenigl, Martin
author_sort Rawlings, Stephen A.
collection PubMed
description Background: Molds and other pathogens induce elevated levels of several cytokines, including interleukin (IL)-6 and IL-8. The objective of this study was to investigate the prognostic value of IL-6 and IL-8 as well as fungal biomarkers in blood and bronchoalveolar lavage fluid (BAL) for overall survival in patients with underlying hematological malignancies and suspected mold infection. Methods: This cohort study included 106 prospectively enrolled adult cases undergoing bronchoscopy. Blood samples were collected within 24 h of BAL sampling and, in a subset of 62 patients, serial blood samples were collected up until 4 days after bronchoscopy. IL-6, IL-8, and other cytokines as well as galactomannan (GM) and β-D-glucan (BDG) were assayed in blood and BAL fluid and associations with overall mortality were assessed at the end of the study using receiver operating characteristic (ROC) curve analysis. Results: Both blood IL-8 (AUC 0.731) and blood IL-6 (AUC 0.699) as well as BAL IL-6 (AUC 0.763) and BAL IL-8 (AUC 0.700) levels at the time of bronchoscopy were predictors of 30-day all-cause mortality. Increasing blood IL-6 levels between bronchoscopy and day four after bronchoscopy were significantly associated with higher 90-day mortality, with similar findings for increasing IL-8 levels. In ROC analysis the difference of blood IL-8 levels between 4 days after bronchoscopy and the day of bronchoscopy had an AUC of 0.829 (95%CI 0.71–0.95; p < 0.001) for predicting 90-day mortality. Conclusions: Elevated levels of IL-6 and IL-8 in blood or BAL fluid at the time of bronchoscopy, and rising levels in blood 4 days following bronchoscopy were predictive of mortality in these patients with underlying hematological malignancy who underwent bronchoscopy for suspected mold infection.
format Online
Article
Text
id pubmed-6687868
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66878682019-08-19 Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection Rawlings, Stephen A. Heldt, Sven Prattes, Juergen Eigl, Susanne Jenks, Jeffrey D. Flick, Holger Rabensteiner, Jasmin Prüller, Florian Wölfler, Albert Neumeister, Peter Strohmaier, Heimo Krause, Robert Hoenigl, Martin Front Immunol Immunology Background: Molds and other pathogens induce elevated levels of several cytokines, including interleukin (IL)-6 and IL-8. The objective of this study was to investigate the prognostic value of IL-6 and IL-8 as well as fungal biomarkers in blood and bronchoalveolar lavage fluid (BAL) for overall survival in patients with underlying hematological malignancies and suspected mold infection. Methods: This cohort study included 106 prospectively enrolled adult cases undergoing bronchoscopy. Blood samples were collected within 24 h of BAL sampling and, in a subset of 62 patients, serial blood samples were collected up until 4 days after bronchoscopy. IL-6, IL-8, and other cytokines as well as galactomannan (GM) and β-D-glucan (BDG) were assayed in blood and BAL fluid and associations with overall mortality were assessed at the end of the study using receiver operating characteristic (ROC) curve analysis. Results: Both blood IL-8 (AUC 0.731) and blood IL-6 (AUC 0.699) as well as BAL IL-6 (AUC 0.763) and BAL IL-8 (AUC 0.700) levels at the time of bronchoscopy were predictors of 30-day all-cause mortality. Increasing blood IL-6 levels between bronchoscopy and day four after bronchoscopy were significantly associated with higher 90-day mortality, with similar findings for increasing IL-8 levels. In ROC analysis the difference of blood IL-8 levels between 4 days after bronchoscopy and the day of bronchoscopy had an AUC of 0.829 (95%CI 0.71–0.95; p < 0.001) for predicting 90-day mortality. Conclusions: Elevated levels of IL-6 and IL-8 in blood or BAL fluid at the time of bronchoscopy, and rising levels in blood 4 days following bronchoscopy were predictive of mortality in these patients with underlying hematological malignancy who underwent bronchoscopy for suspected mold infection. Frontiers Media S.A. 2019-08-02 /pmc/articles/PMC6687868/ /pubmed/31428097 http://dx.doi.org/10.3389/fimmu.2019.01798 Text en Copyright © 2019 Rawlings, Heldt, Prattes, Eigl, Jenks, Flick, Rabensteiner, Prüller, Wölfler, Neumeister, Strohmaier, Krause and Hoenigl. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rawlings, Stephen A.
Heldt, Sven
Prattes, Juergen
Eigl, Susanne
Jenks, Jeffrey D.
Flick, Holger
Rabensteiner, Jasmin
Prüller, Florian
Wölfler, Albert
Neumeister, Peter
Strohmaier, Heimo
Krause, Robert
Hoenigl, Martin
Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection
title Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection
title_full Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection
title_fullStr Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection
title_full_unstemmed Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection
title_short Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection
title_sort using interleukin 6 and 8 in blood and bronchoalveolar lavage fluid to predict survival in hematological malignancy patients with suspected pulmonary mold infection
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687868/
https://www.ncbi.nlm.nih.gov/pubmed/31428097
http://dx.doi.org/10.3389/fimmu.2019.01798
work_keys_str_mv AT rawlingsstephena usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT heldtsven usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT prattesjuergen usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT eiglsusanne usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT jenksjeffreyd usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT flickholger usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT rabensteinerjasmin usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT prullerflorian usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT wolfleralbert usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT neumeisterpeter usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT strohmaierheimo usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT krauserobert usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection
AT hoeniglmartin usinginterleukin6and8inbloodandbronchoalveolarlavagefluidtopredictsurvivalinhematologicalmalignancypatientswithsuspectedpulmonarymoldinfection